Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma

Liang Shun Wang, Kuan Chih Chow, Wing Y. Li, Chia Chuan Liu, Yu Chung Wu, Min Hsiung Huang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Although the serum level of soluble interleukin-2 receptor α (sIL-2Rα) has been shown to correlate with progression and prognosis of several cancers, data to support its clinical significance to esophageal squamous cell carcinoma (ESCC) are limited. This study was conducted to assess the prognostic value and source of sIL-2Rα in patients with ESCC. From January 1986 to June 1997, 125 patients with histopathologically confirmed ESCC were enrolled for study. Ninety-three patients underwent en bloc esophagectomy, and 32 patients with unresectable tumor underwent palliative surgery. Four (4.3%; 4 of 93) patients died of surgical complications. Serum levels of sIL- 2Rα were measured by ELISA. Expression of IL-2Rα, IL-2Rβ, and IL-2Rγ in the pathological section was determined, respectively, by immunohistochemistry (IHC) and in situ hybridization (ISH). Compared with the healthy control group (1020 ± 476 pg/ml, n = 103), ESCC patients tended to have significantly higher serum sIL-2Rα concentrations (1424 ± 798 pg/ml, n = 121). The sIL-2Rα level was correlated with age, Tumor-Node-Metastasis classification, tumor stage, reading score of the IHC staining, and survival but not with the pathological grade or lymphovascular invasion. Prognosis was worse for patients with high sIL-2Rα levels (≥1500 pg/ml) than for those with low serum sIL-2Rα levels (<1500 pg/ml; P = 0.0209). It can be used as an independent prognostic factor of ESCC. In the pathological sections, expression of IL-2Rα, IL-2Rβ, and IL-2Rγ was detected in 17 (18.1%), 83 (89.2%), and 83 (89.2%) cases, respectively, by IHC, and the message of IL- 2Rα was identified in tumor cells by ISH in 30.1% (28 of 93) of the cases. Serum concentrations of sIL-2Rα are frequently elevated in ESCC patients and are correlated with disease progression and survival. These data indicate that, in addition to activated T cells, cancer cells could be an important source of sIL-2Rα in ESCC patients.

Original languageEnglish
Pages (from-to)1445-1451
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number4
Publication statusPublished - Apr 2000
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
Serum
Neoplasms
Immunohistochemistry
In Situ Hybridization
Esophageal Squamous Cell Carcinoma
Esophagectomy
Survival
Palliative Care
Disease Progression
Reading
Enzyme-Linked Immunosorbent Assay
Staining and Labeling
Neoplasm Metastasis
T-Lymphocytes
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wang, L. S., Chow, K. C., Li, W. Y., Liu, C. C., Wu, Y. C., & Huang, M. H. (2000). Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma. Clinical Cancer Research, 6(4), 1445-1451.

Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma. / Wang, Liang Shun; Chow, Kuan Chih; Li, Wing Y.; Liu, Chia Chuan; Wu, Yu Chung; Huang, Min Hsiung.

In: Clinical Cancer Research, Vol. 6, No. 4, 04.2000, p. 1445-1451.

Research output: Contribution to journalArticle

Wang, LS, Chow, KC, Li, WY, Liu, CC, Wu, YC & Huang, MH 2000, 'Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma', Clinical Cancer Research, vol. 6, no. 4, pp. 1445-1451.
Wang, Liang Shun ; Chow, Kuan Chih ; Li, Wing Y. ; Liu, Chia Chuan ; Wu, Yu Chung ; Huang, Min Hsiung. / Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 4. pp. 1445-1451.
@article{f94347b927874632a8de7d1d709cf63e,
title = "Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma",
abstract = "Although the serum level of soluble interleukin-2 receptor α (sIL-2Rα) has been shown to correlate with progression and prognosis of several cancers, data to support its clinical significance to esophageal squamous cell carcinoma (ESCC) are limited. This study was conducted to assess the prognostic value and source of sIL-2Rα in patients with ESCC. From January 1986 to June 1997, 125 patients with histopathologically confirmed ESCC were enrolled for study. Ninety-three patients underwent en bloc esophagectomy, and 32 patients with unresectable tumor underwent palliative surgery. Four (4.3{\%}; 4 of 93) patients died of surgical complications. Serum levels of sIL- 2Rα were measured by ELISA. Expression of IL-2Rα, IL-2Rβ, and IL-2Rγ in the pathological section was determined, respectively, by immunohistochemistry (IHC) and in situ hybridization (ISH). Compared with the healthy control group (1020 ± 476 pg/ml, n = 103), ESCC patients tended to have significantly higher serum sIL-2Rα concentrations (1424 ± 798 pg/ml, n = 121). The sIL-2Rα level was correlated with age, Tumor-Node-Metastasis classification, tumor stage, reading score of the IHC staining, and survival but not with the pathological grade or lymphovascular invasion. Prognosis was worse for patients with high sIL-2Rα levels (≥1500 pg/ml) than for those with low serum sIL-2Rα levels (<1500 pg/ml; P = 0.0209). It can be used as an independent prognostic factor of ESCC. In the pathological sections, expression of IL-2Rα, IL-2Rβ, and IL-2Rγ was detected in 17 (18.1{\%}), 83 (89.2{\%}), and 83 (89.2{\%}) cases, respectively, by IHC, and the message of IL- 2Rα was identified in tumor cells by ISH in 30.1{\%} (28 of 93) of the cases. Serum concentrations of sIL-2Rα are frequently elevated in ESCC patients and are correlated with disease progression and survival. These data indicate that, in addition to activated T cells, cancer cells could be an important source of sIL-2Rα in ESCC patients.",
author = "Wang, {Liang Shun} and Chow, {Kuan Chih} and Li, {Wing Y.} and Liu, {Chia Chuan} and Wu, {Yu Chung} and Huang, {Min Hsiung}",
year = "2000",
month = "4",
language = "English",
volume = "6",
pages = "1445--1451",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma

AU - Wang, Liang Shun

AU - Chow, Kuan Chih

AU - Li, Wing Y.

AU - Liu, Chia Chuan

AU - Wu, Yu Chung

AU - Huang, Min Hsiung

PY - 2000/4

Y1 - 2000/4

N2 - Although the serum level of soluble interleukin-2 receptor α (sIL-2Rα) has been shown to correlate with progression and prognosis of several cancers, data to support its clinical significance to esophageal squamous cell carcinoma (ESCC) are limited. This study was conducted to assess the prognostic value and source of sIL-2Rα in patients with ESCC. From January 1986 to June 1997, 125 patients with histopathologically confirmed ESCC were enrolled for study. Ninety-three patients underwent en bloc esophagectomy, and 32 patients with unresectable tumor underwent palliative surgery. Four (4.3%; 4 of 93) patients died of surgical complications. Serum levels of sIL- 2Rα were measured by ELISA. Expression of IL-2Rα, IL-2Rβ, and IL-2Rγ in the pathological section was determined, respectively, by immunohistochemistry (IHC) and in situ hybridization (ISH). Compared with the healthy control group (1020 ± 476 pg/ml, n = 103), ESCC patients tended to have significantly higher serum sIL-2Rα concentrations (1424 ± 798 pg/ml, n = 121). The sIL-2Rα level was correlated with age, Tumor-Node-Metastasis classification, tumor stage, reading score of the IHC staining, and survival but not with the pathological grade or lymphovascular invasion. Prognosis was worse for patients with high sIL-2Rα levels (≥1500 pg/ml) than for those with low serum sIL-2Rα levels (<1500 pg/ml; P = 0.0209). It can be used as an independent prognostic factor of ESCC. In the pathological sections, expression of IL-2Rα, IL-2Rβ, and IL-2Rγ was detected in 17 (18.1%), 83 (89.2%), and 83 (89.2%) cases, respectively, by IHC, and the message of IL- 2Rα was identified in tumor cells by ISH in 30.1% (28 of 93) of the cases. Serum concentrations of sIL-2Rα are frequently elevated in ESCC patients and are correlated with disease progression and survival. These data indicate that, in addition to activated T cells, cancer cells could be an important source of sIL-2Rα in ESCC patients.

AB - Although the serum level of soluble interleukin-2 receptor α (sIL-2Rα) has been shown to correlate with progression and prognosis of several cancers, data to support its clinical significance to esophageal squamous cell carcinoma (ESCC) are limited. This study was conducted to assess the prognostic value and source of sIL-2Rα in patients with ESCC. From January 1986 to June 1997, 125 patients with histopathologically confirmed ESCC were enrolled for study. Ninety-three patients underwent en bloc esophagectomy, and 32 patients with unresectable tumor underwent palliative surgery. Four (4.3%; 4 of 93) patients died of surgical complications. Serum levels of sIL- 2Rα were measured by ELISA. Expression of IL-2Rα, IL-2Rβ, and IL-2Rγ in the pathological section was determined, respectively, by immunohistochemistry (IHC) and in situ hybridization (ISH). Compared with the healthy control group (1020 ± 476 pg/ml, n = 103), ESCC patients tended to have significantly higher serum sIL-2Rα concentrations (1424 ± 798 pg/ml, n = 121). The sIL-2Rα level was correlated with age, Tumor-Node-Metastasis classification, tumor stage, reading score of the IHC staining, and survival but not with the pathological grade or lymphovascular invasion. Prognosis was worse for patients with high sIL-2Rα levels (≥1500 pg/ml) than for those with low serum sIL-2Rα levels (<1500 pg/ml; P = 0.0209). It can be used as an independent prognostic factor of ESCC. In the pathological sections, expression of IL-2Rα, IL-2Rβ, and IL-2Rγ was detected in 17 (18.1%), 83 (89.2%), and 83 (89.2%) cases, respectively, by IHC, and the message of IL- 2Rα was identified in tumor cells by ISH in 30.1% (28 of 93) of the cases. Serum concentrations of sIL-2Rα are frequently elevated in ESCC patients and are correlated with disease progression and survival. These data indicate that, in addition to activated T cells, cancer cells could be an important source of sIL-2Rα in ESCC patients.

UR - http://www.scopus.com/inward/record.url?scp=0034007146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034007146&partnerID=8YFLogxK

M3 - Article

C2 - 10778976

AN - SCOPUS:0034007146

VL - 6

SP - 1445

EP - 1451

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -